- Innocan Pharma Corporation (INNO) has announced close to 100 per cent bioavailability following subcutaneous injection of its CBD proprietary LPT delivery system in a clinical study conducted on dogs suffering from pain
- Harvard Medical School describes CBD or cannabidiol as an active ingredient in cannabis that is derived from the hemp plant but does not cause a high and is not addictive
- When CBD is administered orally in humans, bioavailability levels of between 6.5-20 per cent of administered dosage is achieved
- By administering injectable CBD encapsulated in liposomes (the LPT platform), Innocan seeks to achieve long-lasting and therapeutic levels of CBD in the body
- Innocan is a pharmaceutical tech company that operates under two main segments: pharmaceuticals and consumer Wellness
- InnoCan Pharma Corporation opened trading at $0.48 per share
Innocan Pharma (INNO) has announced results from a clinical study on dogs suffering from pain.
The company reported close to 100 per cent bioavailability following subcutaneous injection of its CBD proprietary LPT delivery system.
Harvard Medical School describes CBD or cannabidiol as an active ingredient in cannabis that is derived from the hemp plant but does not cause a high and is not addictive.
When CBD is administered orally in humans, bioavailability levels of between 6.5-20 per cent of administered dosage is achieved.
Bioavailability refers to the exposure to the drug in the blood circulation when administered extra vascularly compared to the exposure obtained following intravenous administration, when normalized to the dose.
The low oral bioavailability of CBD in people (6.5 per cent) is a result of first pass metabolism in the liver and considered to be variable and dependent on fasting/fed conditions.
By administering injectable CBD encapsulated in liposomes (the LPT platform), Innocan seeks to achieve long-lasting and therapeutic levels of CBD in the body. The company believes this will create a far more effective and prolonged therapeutic effect.
It carried out a series of experiments of its LPT platform on animals. These experiments have demonstrated initial positive results, supporting the viability of Innocan’s intention to make CBD available to humans and animals for extended periods upon a single injection.
Innocan’s unique delivery method allows for the prolonged release of CBD into the bloodstream with improved pharmacokinetic (PK) performance.
The research is conducted in collaboration with the Hebrew University of Jerusalem and indicates potential for the company’s technology to deliver cannabinoids to the blood stream in a more effective manner.
“One of the challenges with CBD treatments is its pharmacokinetic profile after oral administration that is characterized by low bioavailability and fast elimination,” noted Professor Chezy Barenholz of The Hebrew University.
“Our preliminary data shows that we may overcome these major obstacles using the LPT technology and this is very encouraging,” he added.
“It has been a long time coming, and now Innocan is showing remarkable findings from its CBD bioavailability trial using the LPT technology,” stated Innocan CEO, Iris Bincovich.
“We are optimistic about this being an important piece of information to both our shareholders and the scientific community,” she added.
Innocan also seizes the opportunity to announce the recent appointment of Roni Kamhi as an officer of the company in the position of Chief Operating Officer.
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness.
InnoCan Pharma Corporation opened trading at $0.48 per share.
